| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 1.8 | 1.0 | 1.0 |
| Other income | 0.2 | 0.1 | -0.2 |
| Total income | 2.0 | 1.0 | 0.8 |
| Profit before exceptional items & tax | -0.9 | -0.5 | -1.2 |
| Profit before tax | -0.9 | -0.5 | -1.2 |
| Net profit | -0.3 | -0.5 | -1.1 |
| Operating margin | -45.0% | -50.0% | -150.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Revenue, year on year | +80.00% |
|---|
BSE results filing, NSE: KAPILCO. Figures extracted from the filing.
Skybiotech Healthcare Ltd: key numbers
- Share price
- ₹114.00
- Market cap
- ₹21.83 Cr
- Revenue (annual)
- ₹7.10 Cr
- Net profit (annual)
- ₹-1.12 Cr
- P/E (TTM)
- -13.1×Sector 55.7×
- Promoter holding
- 63.48%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Skybiotech Healthcare Ltd
All →Skybiotech Healthcare Annual General Meeting
Skybiotech Healthcare Ltd has issued the notice for its 43rd Annual General Meeting. The meeting is scheduled to be held on September 30, 2026.
Skybiotech Healthcare Annual Report
Skybiotech Healthcare Ltd has filed its Annual Report for the financial year 2025-26, pursuant to Regulation 34 of the SEBI LODR Regulations.
Skybiotech Healthcare Q1 FY27 Results: Net Loss of ₹0.6 Cr
Skybiotech Healthcare Ltd reported revenue from operations of ₹0.5 Cr (-79.2% YoY) and a net loss of ₹0.6 Cr for Q1 FY27.
- Key figure
- Net loss ₹0.6 Cr